share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/10/01 04:58

Moomoo AI 已提取核心信息

NeuroSense Therapeutics reported financial results for H1 2024, with a net loss of $6.26 million compared to $6.57 million in H1 2023. Research and development expenses decreased 9.4% to $3.45 million, while general and administrative expenses remained stable at $2.57 million. As of June 30, 2024, the company had cash of $1.20 million.The company's lead candidate PrimeC showed positive 12-month data from the PARADIGM clinical trial in ALS treatment, demonstrating significant improvement in disease progression and survival rates. NeuroSense plans to meet with FDA and EMA in Q4 2024 and commence a pivotal trial in H1 2025.To strengthen its financial position, NeuroSense raised additional capital through multiple offerings in 2024, including a $4.5 million registered direct offering in June and a $0.6 million private placement in August. The company also established a $2.52 million equity program with JonesTrading, under which it has raised $276,000 to date through share sales.
NeuroSense Therapeutics reported financial results for H1 2024, with a net loss of $6.26 million compared to $6.57 million in H1 2023. Research and development expenses decreased 9.4% to $3.45 million, while general and administrative expenses remained stable at $2.57 million. As of June 30, 2024, the company had cash of $1.20 million.The company's lead candidate PrimeC showed positive 12-month data from the PARADIGM clinical trial in ALS treatment, demonstrating significant improvement in disease progression and survival rates. NeuroSense plans to meet with FDA and EMA in Q4 2024 and commence a pivotal trial in H1 2025.To strengthen its financial position, NeuroSense raised additional capital through multiple offerings in 2024, including a $4.5 million registered direct offering in June and a $0.6 million private placement in August. The company also established a $2.52 million equity program with JonesTrading, under which it has raised $276,000 to date through share sales.
NeuroSense Therapeutics公布了2024年上半年的财务业绩，净亏损为626万美元，较2023年上半年的657万美元有所减少。研发支出下降了9.4%，降至345万美元，而一般和管理费用保持稳定，为257万美元。截至2024年6月30日，公司现金为120万美元。公司的主打候选药物PrimeC在ALS治疗的PARADIGm临床试验中显示出积极的12个月数据，显示疾病进展和生存率有显著改善。NeuroSense计划在2024年第四季度与FDA和EMA会面，并在2025年上半年开始一项关键试验。为了加强其财务状况，NeuroSense在2024年通过多次融资筹集了额外资金，包括6月份的450万美元注册直接发行和8月份的60万美元定向增发。公司还与JonesTrading建立了一个252万美元的股权计划，通过股份销售，至今已筹集276,000美元。
NeuroSense Therapeutics公布了2024年上半年的财务业绩，净亏损为626万美元，较2023年上半年的657万美元有所减少。研发支出下降了9.4%，降至345万美元，而一般和管理费用保持稳定，为257万美元。截至2024年6月30日，公司现金为120万美元。公司的主打候选药物PrimeC在ALS治疗的PARADIGm临床试验中显示出积极的12个月数据，显示疾病进展和生存率有显著改善。NeuroSense计划在2024年第四季度与FDA和EMA会面，并在2025年上半年开始一项关键试验。为了加强其财务状况，NeuroSense在2024年通过多次融资筹集了额外资金，包括6月份的450万美元注册直接发行和8月份的60万美元定向增发。公司还与JonesTrading建立了一个252万美元的股权计划，通过股份销售，至今已筹集276,000美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间